LCZ696在慢性心力衰竭中的研究进展

王辉波; 杨俊; 彭娟

doi:10.13201/j.issn.1001-1439.2015.05.002

LCZ696在慢性心力衰竭中的研究进展

- 1 三峡大学心血管病研究所三峡大学第一临床医学院心内科(湖北宜昌, 443003);
- 2 三峡大学医学院
基金项目:
国家自然科学基金(No:81170133,81200088,81470387)

宜昌市科技研究与开发项目(No:A12301-01)

湖北省首届医学领军人才基金(No:鄂卫生计发[2013]4号)

详细信息

作者简介:
杨俊,E-mail:yangjun@medmail.com.cn

中图分类号: R541.6

收稿日期: 2014-11-11

Research progress of LCZ696 in chronic heart failure

- 1 Institute of Cardiovascular Disease, China Three Gorges University, Yichang, Hubei, 443003, China;
- 2 Medical Science College of China Three Gorges University

Received Date: 11 November 2014

摘要

摘要: 慢性心力衰竭(CHF)是大多数心血管疾病的最终归宿,且因具有高发病率、高死亡率而引起人们的关注。LCZ696具有抑制肾素-血管紧张素-醛固酮系统(RASS)和脑啡肽酶的双重作用,成为CHF的一种新治疗方法。本文总结归纳了LCZ696在治疗CHF中的作用及相关机制,并对LCZ696作为一种治疗CHF的新药在前期临床试验中的结果进行简单介绍。
- LCZ696 /
- 慢性心力衰竭 /
- 机制
Abstract: Chronic heart failure(CHF) is the end result of various cardiovascular diseases.It has caused much concern because of its high morbidity and mortality.LCZ696 has dual effect on inhibition of the renin angiotensin aldosterone system(RASS) and the neprilysin,and becomes a new drug for the treatment of CHF.The present review primarily focuses on the related mechanisms of LCZ696 in the treatment of CHF,and makes a brief summary of LCZ696 on its outcomes in preclinical trials as a new drug for CHF.
- LCZ696 /
- chronic heart failure /
- mechanism

HTML全文

参考文献(17)

[1]	GASIOROWSKI A, DUTKIEWICZ J. Comprehensive rehabilitation in chronic heart failure[J]. Ann Agric Environ Med, 2013, 20:606-612.
[2]	ZUCKER I H, XIAO L, HAACK K K V, et al. The central RAS and sympathetic nerve activity in chronic heart failure[J]. Clin Sci (Lond), 2014, 126:695-706.
[3]	MCMURRAY J J V. CONSENSUS to EMPHASIS:the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure[J]. Eur J Heart Fail, 2011,13:929-936.
[4]	VARDENY O, TACHENY T, SOLOMON S D. First-in-class angiotensin receptor neprilysin inhibitor in heart failure[J]. Clin Pharmacol Ther, 2013, 94:445-448.
[5]	ORLY VARDENY P, MILLER R, SOLOMON S D. Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure[J]. JACC Heart Fail, 2014, 6:663-670.
[6]	KOMUKAI K, YAGI H, OGAWA T, et al. Inhibition of the renin-angiotensin system prevents re-hospitalization of heart failure patients with preserved ejection fraction[J]. Circ J, 2008, 72:2004-2008.
[7]	FERRARIO C. Effect of angiotensin receptor blockade on endothelial function:focus on olmesartan medoxomil[J]. Vasc Health Risk Manag, 2009,5:301-314.
[8]	LI C, BOOZE R M, HERSH L B. Tissue-specific expression of rat neutral endopeptidase (neprilysin) mRNAs[J]. J Biolog Chem, 1995, 270:5723-5728.
[9]	STANDEVEN K F, HESS K, CARTER A M, et al. Neprilysin, obesity and the metabolic syndrome[J]. Intern J Obes, 2010, 35:1031-1040.
[10]	NISHIKIMI T, KUWAHARA K, NAKAO K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides[J]. J Cardiol, 2011, 57:131-140.
[11]	MANGIAFICO S, COSTELLO-BOERRIGTER L C, ANDERSEN I A, et al. Neutral endopeptidase inhibition and the natriuretic peptide system:an evolving strategy in cardiovascular therapeutics[J]. Eur Heart J, 2013, 34:886-893.
[12]	KOSTOVA E, JOVANOSKA E, ZAFIROV D, et al. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats[J]. Bratisl Lek Listy, 2005, 106:407-411.
[13]	VOORS A A, DORHOUT B, VAN DER MEER P. The potential role of valsartan+AHU377(LCZ696) in the treatment of heart failure[J]. Expert Opin Investig Drugs, 2013, 22:1041-1047.
[14]	SOLOMON S D, ZILE M, PIESKE B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction:a phase 2 double-blind randomised controlled trial[J]. Lancet, 2012, 380:1387-1395.
[15]	MURRAY J J V, PACKER M, DESAI A S, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure:rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)[J]. Eur J Heart Fail, 2013, 15:1062-1073.
[16]	RAMANI G V, UBER P A, MEHRA M R. Chronic heart failure:contemporary diagnosis and management[C]. Mayo Clinic Proceedings. Elsevier, 2010, 85:180-195.
[17]	MCMURRAY J J V, PACKER M, DESAI A S, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371:993-1004.